104例Ⅱ型糖尿病患者使用瑞易宁的疗效观察

The curative effect of Glipizide XL in 104 cases of type Ⅱ diabetics

目的:评价格列吡嗪控释片(瑞易宁)降糖治疗的有效性和安全性。方法:对104例住院并使用瑞易宁治疗2周以上的Ⅱ型糖尿病患者临床资料进行回顾性分析。观察瑞易宁治疗前后血糖、胰岛素、血脂以及肝肾功能的变化,并对其中28例患者进行格列吡嗪和瑞易宁降糖效果和剂量的比较,对其中53例老年患者进行用药有效性、安全性分析。结果:使用瑞易宁治疗后,空腹血糖由(9.27±3.26)mmolL降至(6.59±1.92)mmolL,共降低了2.68mmolL;餐后血糖由(13.6±1.92)mmolL降至(9.79±3.14)mmolL,共降低了3.81mmolL;糖化血红蛋白由8.41%降至7.06%,下降了1.35%,仅1例发生实验室证实的低血糖。瑞易宁与格列吡嗪的降糖效果相当,但用量明显减少,28例患者格列吡嗪使用的总量在瑞易宁组为345mg,在格列吡嗪组为550mg,前者为后者的23。老年人使用瑞易宁同样安全有效。结论:瑞易宁每天服用一次,可以全天控制空腹和餐后血糖,且低血糖的发生率低,是一种安全、有效的降糖药物。

Objective:To assess the efficacy and safety of Glipizide XL.Methods:104 cases of hospitalized type Ⅱ diabetics which used Glipizide XL were reviewed.Datas of plasma glucose,insulin,lipide,liver and kidney function were observed before and after the treatment.Among all the patients,the efficiency and dosage were compared between Glipizide XL and Glipizide in 28 patients,and the efficacy and safety of Glipizide XL were analyzed in 53 elderly patients.Results:Fast plasma glucose dropped from(9.27±3.26)mmolL to(6.59±1.92)mmolL after the treatment,with the mean decrease of 2.68mmolL;3.81mmolL decline was observed in postprandial plasma glucose which fell from(13.6±1.92)mmolL to(9.79±3.14)mmolL;while HbA1c reduced averagely 1.35%,changed from 8.41% to 7.06%;only one patient had hypoglycemia conformed by laboratory.Furthermore,when the same decline of plasma glucose was detected in 28 diabetics,dosage of Glipizide XL was only two third of that of Glipizide,which was 345mg compared to 550mg.On the other hand,it is also efficient and safe to use Glipizide XL in elderly type Ⅱ patients.Conclusion:Glipizide XL is efficient and safe,which can control fast and postprandial glucose well all day and dosing only once a day with low incidence of hypoglycemia.